Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

PHASE3CompletedINTERVENTIONAL

Enrollment

756

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Ocular HypertensionOpen-angle Glaucoma

Interventions

DRUG

AR-13324 Ophthalmic Solution 0.02%

1 drop once daily (QD), PM, OU

DRUG

Timolol maleate Ophthalmic Solution 0.5% BID

1 drop BID, AM/PM, OU

OTHER

Placebo

1 drop QD, AM, OU

DRUG

AR-13324 Ophthalmic Solution 0.02% BID

1 drop BID, AM/PM, OU

Trial Locations (1)

Aerie Pharmaceuticals, Bedminster